DGAP-News: Medios AG / Key word(s): Quarter Results/Regulatory Admission
Medios AG confirms forecast for 2020 after first quarter – Admission to Prime Standard intended
Berlin, 4 May 2020 – Medios AG (‘Medios’), one of the leading Specialty Pharma companies in Germany, has continued its dynamic growth in the first quarter of 2020. In the period from January to March, group sales increased by 52.1% to €162.8 million compared to the same period of the previous year (€107.0 million). Consolidated earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted for extraordinary expenses*, increased by 19.4% to €4.3 million (previous year €3.6 million). Consolidated earnings before taxes (EBT), adjusted for extraordinary expenses*, climbed by 15.6% to €3.7 million (previous year €3.2 million). The Management Board confirms the full-year forecast.
Matthias Gärtner, CFO of Medios AG: ‘We are very satisfied with the start into the new year. Our business has not been significantly affected by the Corona pandemic so far. This makes us confident for the further course of the year. The growth in the first quarter gives us momentum to reach our targets for 2020. In addition, we expect synergy effects from the acquisition of Kölsche Blister GmbH in the medium term.’
With the acquisition of Kölsche Blister GmbH in the first quarter of 2020, Medios’ business model was expanded with the service of patient-specific blistering. This is the patient-related repackaging of finished pharmaceuticals on individual request.
In addition, Medios has signed an agreement for a syndicated loan in the amount of €62.5 million in the first quarter. This is intended to enable Medios to finance future growth and to make further acquisitions if requested in order to benefit from the consolidation of the pharmaceutical market.
The wider target ranges take into account the special conditions. At present, it is not possible to estimate whether the spread of the Corona virus will have a larger impact on the future business development. So far, it has not been significantly affected by the pandemic however.
Admission to Prime Standard
Matthias Gärtner, CFO of Medios AG: ‘Our goal is to be included in the SDAX as soon as possible. This will enable us to significantly increase the liquidity of our shares and the visibility of Medios on the capital market, especially for international investors.’
* EBITDA and EBT are adjusted for extraordinary expenses for stock options and acquisitions.
About Medios AG
Medios AG is Germany’s first publicly listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard).
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||+49 30 232 566 – 800|
|Fax:||+49 30 232 566 – 801|
|Listed:||Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Dusseldorf|
|EQS News ID:||1034267|
|End of News||DGAP News Service|